UroXatral

Known as: Benestan, Urion, Xatral 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1999-2016
012319992016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
  • Molecular ecology
  • 2016
In an article, we recently published in Molecular Ecology (Benestan et al. 2015) and we documented fine-scale population… (More)
  • figure 1
  • figure 2
Is this relevant?
2012
2012
Benign prostate hyperplasia (BPH) occurs in up to 50% of men by age 50, and the incidence increases with age. This common… (More)
  • figure 1
  • table 1
  • table 2
Is this relevant?
2012
2012
AIM To assess differences in pupil diameter between men taking systemic α(1)-adrenoreceptor antagonists and controls. SETTING… (More)
Is this relevant?
2012
2012
Alfuzosin, a selective alpha-1a antagonistis is the most recently approved AARAS, with limited cardiac toxicity and exclusively… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2009
2009
OBJECTIVE Assess safety and efficacy of 10-mg prolonged-release alfuzosin (Xatral XL) in benign prostatic hyperplasia (BPH… (More)
Is this relevant?
2005
2005
In their paper on the intraoperative floppy iris syndrome (IFIS), Chang and Campbell raise awareness of an important clinical… (More)
Is this relevant?
Review
2002
Review
2002
alpha-adrenoceptor antagonists have traditionally been used in the treatment of hypertension but in recent years they have become… (More)
Is this relevant?
1999
1999
Approximately 25% of men over 40 or 50 suffer from lower urinary tract symptoms (LUTS) caused by benign prostatic hyperplasia… (More)
Is this relevant?